Zai Lab
Zai Lab Ltd is a biopharmaceutical enterprise headquartered in Shanghai, China, and Cambridge, Massachusetts. The company focuses on the discovery, development, and commercialization of innovative oncology, autoimmune, infectious, and neuroscience therapeutics, licensing and partnering advanced drug candidates for the Chinese and global markets. Principal revenue is derived through commercial pharmaceutical product sales of approved specialty medications and collaborative research licensing agreements. Zai Lab Ltd is publicly listed on the Nasdaq Stock Market and the Hong Kong Stock Exchange.
4 of the funds FundTelligence covers report a position in Zai Lab.
- Legal name
- Zai Lab Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 4
Funds holding Zai Lab
- Mercer Global Small Cap Equity Fund — Mercer · 0.08 % (full portfolio disclosed, December 2025)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.04 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)